Johnson & Johnson, US4781601046

Johnson & Johnson stock: Ollin deal and CAPLYTA filing shape week

Published on 11/21/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock was shaped by a USD 2.2 billion Ollin Biosciences deal. A CAPLYTA filing added a second pipeline catalyst.

Two pipeline moves set tone

  • Johnson & Johnson agreed to acquire Ollin Biosciences and add the Phase 3 candidate OLN324 to its ophthalmology pipeline.
  • The company submitted CAPLYTA for potential approval in bipolar mania after two positive Phase 3 studies.
  • The Ollin transaction is expected to close before the end of 2026, subject to approvals and customary conditions.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson set two major pipeline developments in motion during the week of November 16-20. On Monday, November 16, the company announced a definitive agreement to acquire Ollin Biosciences for USD 2.2 billion upfront, with up to approximately USD 1.125 billion in potential regulatory and commercial milestone payments, according to Johnson & Johnson.

Ophthalmology pipeline expands

The proposed acquisition would add OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. Johnson & Johnson said the transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. Blackstone Life Sciences is also expected to fund the Phase 3 development of OLN324 through a separate agreement.

CAPLYTA seeks another indication

On Thursday, November 19, Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for CAPLYTA in manic or mixed episodes associated with bipolar I disorder in adults. The filing is supported by two positive Phase 3 studies, according to the company's press release. If approved, bipolar mania would become the fifth approved use for CAPLYTA in adults.

Johnson & Johnson stock traded at 246.85 euros on Lang & Schwarz at 11:07 CET on Saturday, November 21, 0.06 percent below the Xetra close of Friday, November 20. The Xetra close was 247.00 euros on Friday, compared with 258.55 euros on Friday, November 13, leaving the stock 4.47 percent lower over the week.

Johnson & Johnson stock at a glance

  • Company: Johnson & Johnson
  • ISIN: US4781601046
  • Lang & Schwarz: 246.85 euros at 11:07 CET on November 21, 2026
  • Xetra close: 247.00 euros on November 20, 2026
  • Weekly change: -4.47 percent from November 13 to November 20, 2026

The broader market environment is covered in Current market reports.

More news and analyses on Johnson & Johnson stock.

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70541941 | bgmi